Summit Therapeutics Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
Summit Therapeutics filed a Form S-3 on June 9, 2026 (effective upon filing) and a Prospectus Supplement on November 4, 2026 permitting a selling stockholder to resell up to 108,955,369 common shares issuable upon conversion of 108,955.37 shares of Class A Convertible Preferred Stock. The filing is a legal opinion confirming the shares will be validly issued, fully paid, and nonassessable under Delaware law. No specific conversion price, timing, or identity of the selling stockholder is disclosed in this excerpt.
Why this rating
Substantial dilution (~109M shares) relative to $2.5B market cap (~4% of market value at current price). Selling stockholder secondary offering creates supply overhang; convertible preferred suggests prior financing. Timing and terms opaque.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.